CD274 and glioma: HDACis modulate antitumor immune responses by facilitating T cell chemokine production, augmenting PD-1-targeted immunotherapy effectiveness, and increasing PD-L1 and HLA-DR surface expression on tumor cells, suggesting a potential cooperative effect between HDACis and ICIs for glioma therapy.